HC Wainwright Lowers Aprea Therapeutics (NASDAQ:APRE) Price Target to $1.20

Aprea Therapeutics (NASDAQ:APRE) had its target price reduced by equities research analysts at HC Wainwright from $4.00 to $1.20 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 70.50% from the stock’s current price.

A number of other research firms have also recently issued reports on APRE. Wedbush cut their target price on shares of Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating for the company in a research note on Tuesday, February 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. Finally, Zacks Research raised shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $4.10.

Aprea Therapeutics Trading Down 7.7%

APRE stock opened at $0.70 on Tuesday. Aprea Therapeutics has a 1-year low of $0.55 and a 1-year high of $2.22. The business’s 50 day simple moving average is $0.75 and its 200 day simple moving average is $1.04. The firm has a market capitalization of $8.06 million, a PE ratio of -0.36 and a beta of 1.47.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Monday, March 16th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.06. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%.The business had revenue of $0.00 million during the quarter. As a group, sell-side analysts predict that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC bought a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned approximately 0.67% of Aprea Therapeutics as of its most recent filing with the Securities & Exchange Commission. 34.19% of the stock is owned by institutional investors and hedge funds.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.